Drug Profile
Trimebutine - Labopharm
Alternative Names: Modulon SR; Trimebutine maleateLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Axcan Pharma; Labopharm
- Developer Labopharm
- Class Antispasmodics; Benzoic acids; Gastrokinetics; Irritable bowel syndrome therapies
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 01 Sep 2004 Discontinued - Phase-I for Irritable bowel syndrome in Canada (PO)
- 26 Sep 2002 Phase-I clinical trials in Irritable bowel syndrome in Canada (unspecified route)
- 24 Jul 2002 Labopharm and Axcan have signed a letter of intent on a global licensing agreement